Latest Cancer News

The U.S. Food and Drug Administration (FDA) has approved the F1CDx biomarker test designed to detect mutations in 324 genes and two genomic signatures in cancer patients. In a truly collaborative effort between the FDA and The Centers for Medicare &... Continue Reading

Radiation therapy, or radiotherapy, is a common way to treat cervical cancer. With any treatment of cancer you must first understand your responsibility and your medical team’s role as well as explore treatment options and get a second opinion(s) before... Continue Reading

Patients with myelofibrosis resistant or intolerant to Jakafi (ruxolitinib) may have an alternative treatment option with a novel JAK2-selective inhibitor fedratinib, according to the results of clinical study recently published in the medical journal... Continue Reading

Treatment options for advanced NSCLC fit into 3 main categories… Targeted Therapy – we test lung cancer for specific mutations to see if we have an appropriate targeted medication. Immunotherapy – if targeted therapy is not an option immunotherapy... Continue Reading

A hysterectomy is a common surgical treatment of early stage cancer and precancerous disease of the cervix in women. With any treatment of cancer it is important to first understand your responsibility and your medical team’s role as well as explore... Continue Reading

1) Choose Your Doctor Carefully Surgeons, medical oncologists and radiation oncologists are the primary doctors involved with esophageal cancer and often work in collaboration. Pick your primary oncologist carefully, rely on people you trust including... Continue Reading

From theSpineCommunity Back pain is a symptom associated with over 60 different medical conditions.  These disorders involve a number of different organ systems.  A variety of healthcare professionals have expertise that can be useful in the diagnosis... Continue Reading

Incyte Corporation announced that the first patient has been treated in the RESET pivotal trial evaluating Jakafi®  (ruxolitinib) compared to anagrelide for the treatment of patients with essential thrombocythemia (ET) who are resistant to or intolerant... Continue Reading

1) Choose Your Doctor Carefully Hematologists and oncologists are the primary doctors involved with multiple myeloma and often work in collaboration with stem cell transplant physicians. Pick your primary hematologist/oncologist carefully, rely on people... Continue Reading

-MF and pcALCL Represent the Most Common Subtypes of Cutaneous T-Cell Lymphoma (CTCL)- -FDA Approval Based on Clinical Trial Results from the Phase 3 ALCANZA and Phase 2 Investigator-Sponsored Studies in CTCL- “Cutaneous T-cell lymphoma is a blood cancer... Continue Reading

Premenopausal breast cancer is a biologically distinct and more aggressive disease than postmenopausal breast cancer and is the leading cause of cancer death in women 20-59 years old.1,2 ,3 Historically there younger women were treated the same as their... Continue Reading

The Food and Drug Administration granted regular approval to Alcensa (alectinib), for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. In December... Continue Reading

Next Page »

Swedish Medical Center
Copyright 2017

Seattle, WA